obj in 2004

Monday, 22 November 2004
Company Announcements Office
Australian Stock Exchange Limited By e-Lodgement

500% increase in through-the-skin drug delivery


OBJ Limited (OBJ) announces today that it has achieved a 500% increase in drug
delivery using its Dermaportation technology. The new results, up from a previously
reported 300%, were achieved in continuing development studies by the Western
Australian Biomedical Research Institute.
Caffeine, a compound used throughout the world for the evaluation of the
effectiveness of through-the-skin drug delivery, was used at the Curtin University
Drug Development facility in trials designed to help OBJ refine and further improve
its drug delivery technology.
OBJ’s proprietary Dermaportation technology increased caffeine flux to
19.24 ìg.cm-2.h-1, almost 5 times the normal rate.
The Dermaportation technology, which uses 1,000 times less energy than competitive
drug delivery technologies can be used to administer a broad range of drugs,
therapeutic agents and cosmetic compounds through-the skin.
OBJ plans to commence research into the transdermal delivery of a number of
medically and commercially important drugs in the coming weeks and is planning
human clinical trials for early 2005.
For more information:
David Steinepreis Jeffrey Edwards
Chairman Managing Director
OBJ Research & Development Facility
Level 1,